In cancer research, identifying somatic mutations is crucial for understanding the genetic basis of cancer, developing targeted therapies, and personalizing treatment plans. Mutect2's ability to accurately call somatic variants from next-generation sequencing (NGS) data makes it an invaluable tool for researchers and clinicians. It helps in uncovering novel mutations that could be potential therapeutic targets or biomarkers for cancer.
